Platelet Biogenesis
Boston
Massachusetts
02125-3393
United States
Website: http://plateletbiogenesis.com/
Email: info@plateletbiogenesis.com
About Platelet Biogenesis
Platelet BioGenesis is a Harvard University spinout that is making human platelets from stem cells. We have developed and patented a microfluidic bioreactor, and shown that functional platelets can be generated from human pluripotent stem cell cultures. By removing the volunteer donor, we can make platelets that are cheaper, safer, and available on demand.
YEAR FOUNDED:
2014
LEADERSHIP:
Co-Founder, CEO & CSO: Jonathan Thon, PhD
Co-Founder & Chair of Scientific Advisory Board: Joseph Italiano, PhD
Co-Founder & CBO: Sven Karlsson, CFA, MBA
CAREER:
Please click here for Platelet BioGenesis' job opportunities.
APPROACH
Please click here for Platelet BioGenesis' approach.
19 articles about Platelet Biogenesis
-
Platelet BioGenesis Receives $2.3 Million Award from the Medical Technology Enterprise Consortium to Accelerate Development of Donor-Independent Platelet Production
12/16/2019
Platelet BioGenesis, Inc. (PBG), the leader in stem cell-derived, on-demand human platelets (PLTs+™) and genetically engineered platelet-based therapeutics, announced today it received an award of $2.3 million from the Medical Technology Enterprise Consortium (MTEC) – a 501(c)(3) biomedical technology consortium collaborating with the U.S. Army Medical Research and Development Command (USAMRDC)
-
BioSpace takes a look at some of the financing rounds announced over the past few weeks.
-
Platelet BioGenesis Receives Contract Worth Up to $56 Million from the Biomedical Advanced Research and Development Authority (BARDA) to Develop Human Stem Cell-Derived Platelets as a Medical Countermeasure to Radiological and Nuclear Exposure
10/7/2019
Platelet BioGenesis, Inc. (PBG), the leader in stem cell-derived, on-demand human platelets (PLTs+™) and genetically engineered platelet-based therapeutics, announced today it was awarded a contract worth $5 million, with the potential to reach $56 million total with options, by the Biomedical Advanced Research and Development Authority (BARDA)
-
KILL Platelet BioGenesis Receives $56 Million Contract from the Biomedical Advanced Research and Development Authority (BARDA) to Develop Human Stem Cell-Derived Platelets as a Medical Countermeasure to Radiological and Nuclear Exposure
10/3/2019
Platelet BioGenesis requests that their press release NewsItemId: 20190930005207, "Platelet BioGenesis Receives $56 Million Contract from the Biomedical Advanced Research and Development Authority to Develop Human Stem Cell-Derived Platelets as a Medical Countermeasure to Radiological and Nuclear Exposure" issued on September 30th, 2019 be killed.
-
Platelet BioGenesis Receives $56 Million Contract from the Biomedical Advanced Research and Development Authority (BARDA) to Develop Human Stem Cell-Derived Platelets as a Medical Countermeasure to Radiological and Nuclear Exposure
9/30/2019
Funding will support clinical development of stem cell-derived platelet technology platform
-
Platelet BioGenesis Raises $26 Million in Series A-1 Financing
9/9/2019
Steven Altschuler, M.D., Managing Director of Ziff Capital Partners and Chairman of Spark Therapeutics, joins PBG’s Board of Directors
-
Platelet BioGenesis Signs Lease for New Headquarters in Watertown, Mass.
7/23/2019
Rapidly growing biotech will relocate to new lab and office space in early 2020
-
BioSpace Movers and Shakers: July 3
7/3/2019
Biotech and pharma companies strengthen their executive leadership and board positions. -
Platelet BioGenesis Appoints Biotech Industry Veteran Sam Rasty, Ph.D., as President and Chief Executive Officer
7/1/2019
New leader to rapidly build team and capabilities to scale unique stem cell-derived platelet manufacturing platform, advance core program to the clinic, and establish proof of concept for platelet-based therapeutics
-
Platelet BioGenesis Augments Board of Directors with Oncology and Immunotherapy Industry Leader Richard Murray, Ph.D.
6/4/2019
Platelet BioGenesis announced the addition of Dr. Richard Murray, president and CEO of Jounce Therapeutics, to its board of directors.
-
The polar vortex that brought bone-chilling temperatures to much of the United States earlier this winter highlighted a near constant concern – an inadequate supply of platelets at blood centers across the country.
-
Platelet Biogenesis and Scaled Biolabs to Collaborate to Optimize Platelet Production Platform
10/2/2018
Platelet BioGenesis (PBG), the leader in the production of functional human platelets (PLTs+™) from stem cells and the development of platelet-based therapeutics, and Scaled Biolabs (Scaled) announced the two firms are collaborating to optimize PBG’s unique production process for making human platelets, or PLTs+™. The agreement was announced at the SynBioBeta 2018 biology summit.
-
Platelet BioGenesis Moves to New Cambridge Lab Space to Support Continued Growth
8/1/2018
Move to Nest.Bio Labs comes as company advances its program to commercialize a donor-independent source of lifesaving platelets
-
There has been recent coverage of 3D bioprinting and how it has the potential to create a brave new world of printed organs to be used in biopharma research and maybe someday to even be used in organ transplants.
-
Platelet Biogenesis (PBG) was awarded a two-year, $3.5 million grant from the U.S. Department of Defense (DoD). The funds are to support the company’s proprietary bioreactor to produce therapeutic amounts of platelets.
-
U.S. Department of Defense Awards $3.5 Million Grant to Platelet BioGenesis
6/27/2018
Research award will support development of donor-independent platelets to treat battlefield and civilian casualties
-
Platelet BioGenesis Appoints Leading Hematology Experts and Physicians to Its Scientific Advisory Board
5/31/2018
Platelet Biogenesis is the leader in the production of functional human platelets from stem cells and the development of platelet-based therapeutics
-
Platelet BioGenesis Licenses Induced Pluripotent Stem Cell Technology from iPS Academia Japan
5/9/2018
Agreement gives groundbreaking human platelet company access to crucial technologies as it advances its program to manufacture human platelets at scale
-
Platelet Biogenesis Raises A $10 Million Series A Financing Led By Qiming U.S. Healthcare Fund
6/9/2017